Subject: Non-Small Cell Lung Cancer
How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:
|Patient Type||Total number of patients (treated and not treated)||Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)||Number not treated|
|All Non-Small Cell Lung Cancer (NSCLC) patients|
|Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)|
Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:
|Therapy||Number of Stage IIIB/IV NSCLC patients currently treated|
|Nintedanib + docetaxel|
|Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin|
|Gemcitabine mono or in combination with carboplatin / cisplatin|
|Paclitaxel mono or in combination with carboplatin / cisplatin|
|Doxetaxel mono or in combination with carboplatin / cisplatin|
|Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin|
If your trust does not treat Stage IIIB/IV NSCLC patients and you refer your patients to another trust, please state to which trust patients are referred
|We do not treat lung cancer at this trust. Upon diagnosis the patient would be transferred to one of the treating trusts namely The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust.
Therefore we would not be ‘managing them’ during treatment.